Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP3 | P17936 | 4/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PPM1G | O15355 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | PPM1A | P35813 | 1/20 | 0.40 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158714 | 1.00 | IGFBP3 (0.41) | IGFBP3AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Water SCHEMBL17596689 | 0.98 | IGFBP3 (0.40) | IGFBP3AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Water SCHEMBL30546266 | 0.98 | IGFBP3 (0.40) | IGFBP3AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL13037420 | 0.84 | IGFBP5 (0.35) | IGFBP3PTGESPPM1GALOX5PTPN1 | |
| SCHEMBL304493 | 0.84 | IGFBP5 (0.35) | IGFBP3PTGESPPM1GALOX5PTPN1 | |
| SCHEMBL9463397 | 0.83 | AKR1C4 (0.44) | IGFBP3AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7524860 | 0.82 | KDM4E (0.44) | IGFBP3IGFBP5ALOX15TSHRMEN1 | |
| SCHEMBL9441953 | 0.82 | PTGES (0.39) | IGFBP3AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9391555 | 0.82 | NQO2 (0.40) | AKR1C4AKR1C3AKR1C2AKR1C1PTGES | |
| SCHEMBL2905353 | 0.81 | NQO2 (0.56) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| CN-114828848-A | Intranasal dantrolene administration for the treatment of alzheimer's disease | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619763-A1 | BIOMARKER PANEL FOR BRAIN SPECIFIC ABNORMAL NEUROLOGICAL CONDITIONS USING BIOFLUID SAMPLES | Gryphon Bio, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | disclosed |
| US-12391664-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | EMORY UNIVERSITY (US) | 2025-08-19 | — | — | US | disclosed |
| US-12334188-B2 | Power reduction in a clock buffer of a memory module based upon memory module speed | DELL PRODUCTS L.P. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2022074588-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074587-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114206900-A | Neuroactive steroids and compositions thereof | 萨奇治疗股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114170951-A | Display device | 三星显示有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220059038-A1 | DISPLAY APPARATUS AND DISPLAY SYSTEM HAVING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-24 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | IGFBP3 3777/4885AKR1C4 751/4885AKR1C3 622/4885 |
| US-12396981-B2 | Methods of using DMT | PNMT, HTR6, HTR1A | IGFBP3 3638/4885AKR1C4 3136/4885AKR1C3 3461/4885 |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | IGFBP3 3844/4885AKR1C4 1763/4885AKR1C3 1662/4885 |
| US-20250375421-A1 | METHODS OF USING DMT | PNMT, HTR6, HTR1A | IGFBP3 3638/4885AKR1C4 3136/4885AKR1C3 3461/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | IGFBP3 1223/4885AKR1C4 4727/4885AKR1C3 4601/4885 |
| US-12391664-B2 | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | GRIN2C, GRIN2A, GRIN2B | IGFBP3 4524/4885AKR1C4 4604/4885AKR1C3 4471/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | IGFBP3 1601/4885AKR1C4 1461/4885AKR1C3 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.